2-(4-METHYLPHENYL)-1,2-BENZISOTHIAZOL-3(2H)-ONE, 95.0%, 50mg

2-(2-Chlorophenyl)-2-(methylamino)-6-(thiophen-2-ylmethylidene)cyclohexan-1-one, 98%, 250mg

2-Butylbenzo[d]oxazol-4-amine, 95.0%, 10g

2,6-Bis(trifluoromethyl)benzamide, 97%, 250mg

4-Acridinol, 95.0%, 250mg

Recipientes esterilizables en autoclave con tapa rectangular, 42 l, 1 unidad

1-Bromo-2-(trifluoromethoxy)benzene, 97.0%, 1g

4-(3-ethyl-1,2,4-oxadiazol-5-yl)aniline, 95.0%, 1g

2-([1,1'-Biphenyl]-4-yl)-4-chloro-6-phenyl-1,3,5-triazine>98.0%(HPLC)(N)1g

(S)-6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide, 98%, 250mg

2-Methylhex-2-enoic acid, 95%, 250mg

6-Bromo-3-chloro-4-methylpyridazine, 97%, 10g

2,1,3-Benzoxadiazol-1-ium-1-olate, 97.0%, 500g